Highlights
- Multi-year commercial supply agreement executed with Quansys Biosciences for the manufacturing of ColoSTAT® reagent kits.
- Provides scalable manufacturing capacity to support the ColoSTAT® Access Program and full commercial rollout.
- Reduces manufacturing scale-up and quality system risk, building on two years of successful assay development collaboration.
- RHY’s price structure shifts to a bullish bias following the breakout.
Rhythm Biosciences Ltd (ASX: RHY) surged around 25% after announcing a strategic supply agreement with Quansys Biosciences, a US-based specialist manufacturer of multiplex immunoassay products. The deal strengthens ColoSTAT’s commercial manufacturing pathway and improves supply-chain certainty ahead of rollout.
Rhythm Biosciences Stock Jumps on Commercial Manufacturing Milestone
Under the agreement, Quansys Biosciences will act as the contract manufacturing partner for ColoSTAT® consumable reagent kits, providing commercial-scale manufacturing capacity under a multi-year supply commitment to support the ColoSTAT® Access Program and subsequent commercial launch. The partnership offers flexible manufacturing capacity that can scale with market demand, supported by established global logistics and distribution infrastructure.
The agreement formalises a collaboration spanning more than two years of assay development, prototyping and analytical validation, including the assessment of thousands of test data points. This transition to commercial manufacturing marks a key operational milestone, ensuring reliable, quality-assured supply, reducing execution risk, and delivering cost-of-goods predictability through fixed pricing for the initial two years, with options to extend.
Rhythm Biosciences Breakout Fuels Bullish Momentum — What’s Next for RHY?
From a technical perspective, RHY continues to trade above its double bottom breakout, reinforcing a positive trend. Recent gains, supported by strong volumes, indicate sustained bullish momentum and potential for further upside. The rising trendline acts as dynamic support, and as long as RHY holds above this level, the near-term bullish structure remains intact.

Price remains above its 21-period Simple Moving Average (SMA), indicating sustained near-term strength. The 14-period Relative Strength Index (RSI) sits at 76.10 above the midpoint, reflecting improving bullish momentum after a recovery from lower levels. Key resistance lies near AUD 0.215 and AUD 0.240, which may act as supply zones and cap near-term gains.
Positive Technicals Backed by Strategic Manufacturing Agreement
Rhythm Biosciences Ltd (ASX: RHY) is supported by both positive news and strong technicals. The multi-year manufacturing agreement for ColoSTAT® enhances its path to market and supply-chain readiness. While resistance near AUD 0.215–0.240 may limit short-term gains, the overall outlook remains constructive, with RHY well-positioned to sustain its bullish momentum.






Please wait processing your request...